Medical device company developing Nano-Pulse Stimulation technology for non-thermal tissue ablation in dermatology and oncology.
Medical device company developing Nano-Pulse Stimulation technology for non-thermal tissue ablation in dermatology and oncology.
Sells very little: the dermatology system, CellFX, was a small commercial effort, and effort has since been redirected toward cardiac ablation devices. Spending is funded by investors and loans, with chairman and major shareholder Robert Duggan the main backer.
Moat: narrow (IP / patents). Patented Nano-Pulse Stimulation technology offers a non-thermal ablation approach distinct from laser/RF competitors.
Headquarters: Hayward, California · Founded: 2014 · Employees: 116
Size Pulse Biosciences (PLSE) is a United States Health Care company (Medical Specialties) with a market value of $3.37B, the 1460th largest of 3,085 United States companies the cockpit tracks. Shares closed at $45.83 on 18 Nov 2026.
Performance Over six months the shares gained 75.7%, against +3.2% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 1,637.2% over the last twelve months (peer median +5.7%); the operating margin is -5,821.1% (peer median 8.3%).
Valuation It trades at 2,133.8× enterprise value to sales against a peer median of 4.7× (most expensive of 21).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.49M | $350,000 | $0 | $0 | $700,000 |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | $10,500 | -$1.26M | -$1.18M | -$1.21M | -$12.6M |
| EBITDA | -$85.9M | -$75.9M | -$53.2M | -$42.4M | -$56.7M |
| Net income | -$83.7M | -$72.8M | -$53.6M | -$42.2M | -$58.5M |
| Free cash flow | -$63.7M | -$54.4M | -$36.5M | -$33.2M | -$47.4M |
| Capital expenditure | $370,000 | $335,000 | $125,000 | $121,000 | $401,000 |
| Total debt | $6.36M | $7.53M | $8.90M | $9.14M | $76.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Pulse Biosciences PLSE | $3.37B | +76% | +1,637% | -5,821% | 2,133.8× | n/a |
| InMode INMD | $741M | -8% | +2% | 18% | 0.6× | -10.8% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 3.5× | 5.8% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 4.0× | 9.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PLSE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.8% | +3.0% | 6th lowest of 21 |
| 6-month return | +75.7% | +3.2% | 3rd highest of 21 |
| Distance from 52-week high | -22.2% | -24.0% | 11th highest of 21 |
| Revenue growth (TTM) | +1,637.2% | +5.7% | highest of 21 |
| Operating margin | -5,821.1% | 8.3% | lowest of 20 |
| EV / Sales | 2,133.8× | 4.7× | most expensive of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | 2,133.8× | n/a | n/a |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 5.0× | -0.4% | +7.2% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 5.1× | 38.4% | +88.2% |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 11.5× | 52.6% | +14.9% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 6.9× | n/a | n/a |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 3.7× | 10.0% | +10.0% |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 4.8× | 22.9% | -16.1% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 1.2× | 8.6% | +8.9% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 4.1× | 8.7% | -4.2% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 3.9× | 46.9% | +23.0% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 1.6× | 12.5% | +10.8% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 3.5× | 45.4% | +3.8% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 4.8× | -1.2% | +8.1% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | 5.9× | 43.7% | -0.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 3.3× | 12.7% | +11.0% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 1.5× | 4.8% | +7.1% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 23.6× | -6.6% | -7.4% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 7.4× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 1.7× | -5.5% | +11.3% |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 4.6× | 54.2% | +20.9% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 5.0× | n/a | n/a |